pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,462 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • How Butterfly, once known for its handheld ultrasound device, is growing its chip-making business
    Nvidia got its start as a gaming chip maker before meteoric success selling its chips to nearly every industry. One health tech company is hoping to go down a similar route. Last month, ultrasoun…
    Endpoints · 24d ago↗ source
  • STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug
    A federal judge blocked a Colorado state panel from placing a cap on the price of Enbrel, a blockbuster drug sold by Amgen
    STAT · 24d ago↗ source
  • STAT+: More frequent, more intense, and longer heat waves pose health risks for Americans
    The presidential fitness test is back, surprising new data on the health risks of obesity, and more Morning Rounds news
← prev
page 20 of 59
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
STAT · 24d ago
↗ source
  • Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study
    Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head trial. Full data haven't yet emerged, but if the drug's survival benefit…
    Endpoints · 24d ago↗ source
  • Ex-iTeos CEO starts fresh at GSK neuro partner; Genentech loses yet another key scientist
    → Michel Detheux has succeeded Rita Balice-Gordon as CEO of Danish neuro biotech Muna Therapeutics, which is partnering with GSK on Alzheimer’s treatments. Balice-Gordon will slide over to ...
    Endpoints · 24d ago↗ source
  • BrightGene looks to the West as obesity shot nears China approval
    Armed with impressive Phase 3 data, BrightGene is taking its obesity shot to Chinese regulators. It expects trial data in the West to be even stronger, but its search for a partner for ex-China ter…
    Endpoints · 24d ago↗ source
  • STAT+: Halfway into the year, biotech is booming
    The biotech stock rally that began in April 2025 has not stopped, and if anything, has accelerated.
    STAT · 24d ago↗ source
  • Opinion: Teens are turning to chatbots for mental health help. We need rules to keep them safe
    The share of young people using AI chatbots for mental health advice rose more than 40% in a single year, researcher writes.
    STAT · 24d ago↗ source
  • Opinion: CDC leadership continues to try to manufacture a scientific debate on vaccines where none exists
    CDC leadership continues to try manufacture a scientific debate on vaccines where none exists, writes Ben Lopman.
    STAT · 24d ago↗ source
  • STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong
    Companies are being too conservative in how they interpret FDA's AI guidance, but the agency can do more to help, too, Tala Fakhouri says.
    STAT · 24d ago↗ source
  • STAT+: A year after distressed buyout, what’s become of Bluebird Bio?
    Bluebird Bio was a dark biotech morality tale when David Meek bought it. He says the new company, Genetix, is already making money.
    STAT · 24d ago↗ source
  • The new presidential fitness test is a positive step, not the solution, experts say
    Physical activity needs to be fun to keep kids engaged. And the test risks embarrassing them, instead.
    STAT · 24d ago↗ source
  • STAT+: A ‘historic’ FDA clearance raises the question: Is the LLM an interface or the decision-maker?
    The newly cleared device is based around an app that helps a patient manage their diabetes using a treatment plan defined by their doctor.
    STAT · 24d ago↗ source
  • Statins and blood pressure drugs changing health risks of obesity, study suggests
    New research shows obesity patients over 40 are managing blood pressure and cholesterol as well as healthy-weight peers, but younger adults remain at risk.
    STAT · 25d ago↗ source
  • Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria
    Merck has axed a Phase 2 trial testing an experimental Alzheimer’s medicine, Endpoints News has learned. The company terminated a mid-stage test of the oral drug candidate MK-1167, a Merck spokes…
    Endpoints · 25d ago↗ source
  • FDA warns Genzyme's Irish site over quality questions
    An FDA warning letter sent late last month to Genzyme's Ireland-based manufacturing site, now owned by Sanofi, raises significant quality- and data-related issues. On data integrity, the warning…
    Endpoints · 25d ago↗ source
  • WuXi AppTec seeks injunction over China military list
    WuXi AppTec has filed for a preliminary injunction to suspend its place on the Pentagon’s list of companies with alleged ties to the Chinese military. The injunction, dated June 29, seeks to stop…
    Endpoints · 25d ago↗ source
  • FDA approves Orca Bio’s cell therapy to improve transplant outcomes
    The FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients. The therapy will be branded as Tregzi, an homage to the regula…
    Endpoints · 25d ago↗ source
  • STAT+: The moment Anthropic convinced me it’s serious about science
    AI Prognosis: The release of Claude Science suggests big model makers are getting serious about real science, and not just flashy problems.
    STAT · 25d ago↗ source
  • BridgeBio adds $1B as it prepares three more drug launches
    BridgeBio Pharma has reloaded with about $1 billion in a preferred equity deal to bolster its reserves ahead of three potential drug launches over the next year. The California biotech, which for…
    Endpoints · 25d ago↗ source
  • STAT+: Synthetic biology researchers think they’ve made a cell. Is it alive?
    Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with other scientists.  It’s a piece…
    STAT · 25d ago↗ source
  • STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more
    Anthropic announced the availability of Claude Science, which optimizes its large language model for use in scientific labs and by drugmakers
    STAT · 25d ago↗ source
  • STAT+: More signs that GLP-1s may help with peripheral artery disease
    Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout
    STAT · 25d ago↗ source
  • 92Bio revives a T cell engager it had transferred to Amgen
    A small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug…
    Endpoints · 25d ago↗ source
  • Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data
    🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had a lumbar interbody fusion, according…
    Endpoints · 25d ago↗ source